Nanjing Vazyme Biotech Co., Ltd (SHA:688105)
China · Delayed Price · Currency is CNY 19.50
-0.12 (-0.61%)
Sep 11, 2026, 3:00 PM CST
Nanjing Vazyme Biotech Market Cap
Nanjing Vazyme Biotech has a market cap or net worth of 10.08 billion as of September 11, 2026. Its market cap has increased by 11.71% in one year.
Market Cap
10.08B
Enterprise Value
8.23B
Revenue
1.47B
Ranking
n/a
PE Ratio
n/a
Stock Price
19.50
ChartMarket Cap Chart
Since November 15, 2021, Nanjing Vazyme Biotech's market cap has decreased from 34.14B to 10.08B, a decrease of -70.47%. That is a compound annual growth rate of -22.34%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 11, 2026 | 10.08B | 26.61% |
| Dec 31, 2025 | 7.96B | -9.63% |
| Dec 31, 2024 | 8.81B | -31.21% |
| Dec 29, 2023 | 12.81B | -39.74% |
| Dec 30, 2022 | 21.26B | -49.87% |
| Dec 31, 2021 | 42.40B | 24.19% |
| Nov 15, 2021 | 34.14B | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Chengdu Olymvax Biopharmaceuticals | 11.83B |
| Chengzhi | 11.50B |
| Inner Mongolia Furui Medical Science | 11.46B |
| Tibet Cheezheng Tibetan Medicine | 11.46B |
| InventisBio | 11.36B |
| Mabwell (Shanghai) Bioscience | 11.20B |
| Hualan Biological Vaccine | 10.81B |
| Jiangxi Fushine Pharmaceutical | 10.75B |